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Background: Patients with rheumatoid arthritis (RA) are known to be at increased risk of vascular disease. It is not
known whether screening for vascular risk factors occurs in primary care. The aim of this study was to determine
whether guidance advocating cardiovascular screening in RA patients is being implemented in primary care.
Methods: This study was undertaken in a UK primary care consultation database. All patients with a diagnosis of
RA between 2000 and 2008, and still registered with the GP practice in 2009 were matched by age, gender and GP
practice to three non-RA patients. Evidence of screening for five traditional vascular risk factors (blood pressure,
lipids, glucose, weight, smoking) was compared in those with and without RA using logistic regression models. A
comparison was also made with diabetes.
Results: 401 RA patients were identified and matched to 1198 non-RA patients. No differences in the overall rates
of screening were found (all five risk factors: RA 24.9% vs no RA 25.6%), but RA patients were more likely to have a
smoking status recorded (67% versus 62%). In contrast, those with diabetes were up to 12 times as likely to receive
vascular screening.
Conclusions: Despite the excess risk of vascular disease in patients with RA being of a similar magnitude to that
seen in diabetes, patients with RA did not receive additional CVD screening in primary care, although this was
achieved in patients with diabetes. More emphasis needs to be placed on ensuring those with RA are actively
screened for cardiovascular disease in primary care.Background
It is well recognised that patients with rheumatoid arth-
ritis (RA) have an increased mortality rate compared
to the general population, due mainly to an excess risk
of cardiovascular disease (CVD) [1-3]. This is reflected
in both the European League Against Rheumatism
(EULAR) and British Society for Rheumatology guide-
lines, which recommend regular CVD screening and ag-
gressive risk factor management in patients with RA
[4,5]. However, it is recognised that traditional CVD risk
assessment tools, such as the Framingham score, sub-
stantially underestimate the risk of cardiovascular dis-
ease in patients with RA [6]. To mitigate this EULAR
guidelines [5] recommend an adjustment by a factor of
1.5 in the presence of specific criteria (disease duration
greater than 10 years, rheumatoid factor or anti-cyclic* Correspondence: s.muller@keele.ac.uk
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reproduction in any medium, provided the orcitrullinated peptide positivity and the presence of extra-
articular manifestations of RA) when traditional CVD
screening tools are used. However, the work of Crowson
et al. [6] suggests that at older ages, even an adjustment
factor of 1.5 may be insufficient. QRISK2 is the only vali-
dated CVD risk assessment tool to include RA as an in-
dependent risk factor for CVD [7], and indeed other UK
guidance from the Joint British Societies Guidance 2 [8]
fails to mention rheumatoid arthritis, further contribut-
ing to the lack of awareness of the increased risk of
CVD in patients with RA. Studies suggest that the excess
CVD risk in RA is comparable to that seen in type 2 dia-
betes mellitus, with an approximate doubling of the risk
of CVD over three years [9,10]. For patients with dia-
betes this has been translated into UK guidance advocat-
ing annual screening and management of CVD risk [11],
further supported with vascular risk factor screening
for patients with diabetes being incentivised as part of
the UK General Practice Quality Outcomes Framework
(QOF), ensuring high uptake of screening for thesetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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screening for patients with RA, few studies have
addressed whether this is being implemented in routine
clinical care or where this screening should occur. The
primary aim of this study therefore was to determine
CVD screening practice in RA and comparable non-RA
patients in a UK-based primary care population prior to
the introduction of an incentivised annual review, which
includes an assessment of CVD risk. A secondary aim
was to compare rates of screening in people with RA to
such rates in people with diabetes mellitus, who have
similarly increased levels of vascular risk and in whom
such screening is incentivised in the UK.
Methods
Identification of RA and non-RA patients
Data were extracted from the Consultations in Primary
Care Archive (CiPCA), an anonymised database of clinical
information from nine general practices in Staffordshire,
UK [13]. RA patients were identified using diagnostic Read
codes. Read codes are a hierarchical coding structure that
all family physicians in the UK use to record diagnoses,
symptoms or procedures in electronic patient records. Ra-
ther than having an administrative purpose, these codes
are used to record clinical care and improve its efficiency.
All patients with a diagnostic Read Code for RA in the
CiPCA database between 2000 and 2008 and still regis-
tered with the practice in 2009 were identified. RA pa-
tients were matched by age, gender and general practice
to three patients without an RA Read coded diagnosis.
Non-RA patients had to have consulted in the year in
which the matched RA patient was first recorded as hav-
ing RA, and also still be registered with the practice in
2009. The practices that contribute to CiPCA are part of
the Keele GP Research Partnership and are subject to
regular cycles of training, assessment and feedback,
which help to ensure that the quality of the data is high
[14]. CiPCA has been shown to give similar prevalence
estimates for musculoskeletal disease as other national
databases [13].
Ethical approval
Approval for download and research using these data-
bases was gained from the North Staffordshire Research
Ethics Committee (REC Reference: 03/04).
Identification of screening and comorbidity
The CiPCA databases for 2009 were searched for Read
codes indicating screening of five traditional CVD risk
factors; blood pressure, lipid levels, smoking status, body
weight or body mass index and blood glucose. These
traditional CVD risk factors were selected as they are
routinely identified and managed in primary care. Re-
cords for 2009 were also searched for morbidity codesand related prescriptions that indicated a diagnosis of
diabetes mellitus, hypertension or hyperlipidaemia. We
sought these diagnoses specifically, as they would in-
crease future CVD screening. We took a cross-sectional
approach to the use of data from 2009 only for analysis
purposes. A list of Read codes used to identify RA pa-
tients, screening and comorbidities is available from the
authors on request.
Definition of screening outcomes
Although, in the UK, the National Institute for Health
and Clinical Excellence recommends adults aged 40 to
74 years are screened for CVD, the priority for full risk
estimation is those considered to be at high risk (10 year
risk of CVD ≥20%). RA patients are also considered high
risk [1-5]. Following the screening recommendations,
CVD screening was defined in three ways: 1) “Any CVD
screening” – screening for any one or more of the five
factors; 2) “Standard CVD screening” – screening of
blood pressure, smoking and lipids – these three fac-
tors were chosen since after accounting for age and
gender, they are responsible for up to 80% of CVD risk
in the general population [15]; and 3) “Comprehensive
screening” – screening for all five factors.
Statistical analyses
Basic demographic information was summarised using
descriptive statistics, chi squared tests and t-tests to
assess differences in screening between RA and non-
RA patients as appropriate. The rates of primary care
contacts (number of days with a contact with primary
care) in 2009 were compared between those with and
without RA. Logistic regression models, both un-
adjusted and adjusted for age and gender, were used to
assess the association between each of the screening
outcomes and RA status. Models were checked for the
presence of correlation between patients within prac-
tices and formulated accordingly. The odds of screen-
ing in patients with RA and those with diabetes
mellitus, hypertension and hyperlipidaemia were also
compared using logistic regression. Results of all logis-
tic regression analyses are presented as odds ratios
with 95% confidence intervals. Statistical analyses were
performed using Stata version 12.1 [16].
Results
Demographics of the study sample
401 RA patients were identified and successfully
matched to 1198 controls (Table 1). As expected for an
RA cohort 265 (66.1%) patients were female and the
mean (standard deviation) age was 58.8 (12.7) years. The
prevalence of diagnosed diabetes mellitus (12.0% vs.
10.6%, p=0.447) and hyperlipidaemia (33.4% vs. 33.2%,
p=0.943) were very similar in RA and non-RA patients






Female Gender 265 (66.1) 793 (66.2)
Age groups (years)
27-50 97 (24.2) 291 (24.3)
51-65 181 (45.1) 543 (45.3)
66-74 79 (19.7) 237 (19.8)
75+ 44 (11.0) 127 (10.6)
Diabetes 48 (12.0) 127 (10.6) 0.447
Hypertension 209 (52.1) 547 (45.7) 0.025
Hyperlipidaemia 134 (33.4) 398 (33.2) 0.943
Mean number of contacts (SD) 18.9 (12.0) 11.4 (10.6) <0.001
RA – Rheumatoid arthritis; SD – standard deviation.
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significantly greater amongst RA patients (52.1% vs.
45.7%, p=0.025). In addition, RA patients had signifi-
cantly more primary care contacts in 2009 than those
without RA (18.9 vs. 11.4, p<0.001).
Rates of screening for cardiovascular risk factors
Blood pressure was the most commonly recorded risk
factor amongst both RA and non-RA patients, with over
70% of patients having a blood pressure measurement
(Table 2). Conversely, measurement of lipids was the risk
factor least likely to be recorded amongst both groups
(RA 45.9%; no RA 43.6%). The rate of screening was
similar between RA and non-RA patients for all risk
factors except smoking status, which was more likely to
be recorded in patients with RA (67.1% vs. 61.6%,
p=0.049) (Table 2).
Rates of CVD screening
There was no evidence of correlation of patients within
GP practice and so single-level logistic regression
models were employed. RA patients had greater odds of
receiving ‘any CVD screening’ than non-RA patients,
even after adjustment for age, gender and comorbidity
(OR 1.59 (1.13, 2.23)) (Table 3). This was due mainly to
the increased recording of smoking status in those withTable 2 RA and non-RA patients screened for each
cardiovascular risk factor (n (%))
Risk factor RA (n=401) Non-RA (n=1198) P-value
Blood pressure 299 (74.6) 860 (71.8) 0.281
Lipids 184 (45.9) 522 (43.6) 0.420
Smoking status 269 (67.1) 738 (61.6) 0.049
Body weight 219 (54.6) 632 (52.8) 0.518
Glucose level 188 (46.9) 565 (47.2) 0.923
RA – Rheumatoid arthritis.RA. However the odds of receiving a standard (blood
pressure, smoking and lipids) (1.01 (0.79, 1.29)) or com-
prehensive (all five factors) (0.96 (0.73, 1.25)) CVD screen
were similar in RA and non-RA patients (Table 3).
The effect of comorbidity on standard CVD screening
rates
The impact of other conditions and RA on rates of
standard CVD screening was explored further by com-
paring the odds of screening in those with either one
or both conditions compared to those with neither
(Table 4). Individuals with diabetes without RA had over
eleven times the odds of receiving a standard CVD
screen (11.14 (6.86, 18.11)). However, the addition of RA
in individuals with diabetes did little to alter their odds
of screening (15.32 (6.70, 35.02)). A similar pattern was
seen in relation to comprehensive screening (data not
shown). Similar effects were seen with hyperlipidaemia
although the effect was less marked for hypertension,
in that the addition of RA failed to increase the odds
of screening.
Discussion
This study found that patients with RA received similar
rates of CVD screening as age, gender and practice
matched non-RA patients, despite consulting more often
in primary care. The exception to this was smoking sta-
tus, which was more likely to be recorded in RA pa-
tients. In contrast, patients with a diagnosis of diabetes
mellitus were significantly more likely to receive any,
standard or comprehensive CVD screening. This sug-
gests that although effective identification of high-risk
patients with diabetes occurs in primary care and prompts
screening, either RA patients are not recognised as
high-risk or this increased risk is recognised but not
translated into more CVD screening. Given that rates
of primary care contact were greater amongst RA pa-
tients, our results cannot be explained by these patients
receiving a large amount of contact with secondary care
and a corresponding lack of contact with primary care.
There are a number of strengths and weaknesses that
need to be considered when interpreting this study.
Compared to existing studies of CVD screening in RA,
with small secondary care populations (n<135) [17-19],
ours is a large sample. The study also benefited from
quality morbidity coding, ensuring that primary care
screening and comorbidities were unlikely to be missed.
Despite the relatively local nature of this database, previ-
ous work by Jordan et al. [13], suggests that local data-
bases such as CiPCA are comparable to larger national
databases. Also, although the CiPCA is known to pro-
vide high quality coding of clinical activity in primary
care, it does not include a complete record of what hap-
pens to patients in secondary care. It is therefore
Table 3 Association between RA status and receiving CVD screening
Type of CVD screen RA (n (%)) Non-RA (n (%)) Unadjusted (OR (95% CI)) Age and gender adjusted (OR (95% CI))
Any 352 (87.8) 983 (82.1) 1.57 (1.13, 2.19) 1.59 (1.13, 2.23)
Standard 138 (34.4) 407 (34.0) 1.02 (0.80, 1.29) 1.01 (0.79, 1.29)
Comprehensive 100 (24.9) 307 (25.6) 0.96 (0.74, 1.25) 0.96 (0.73, 1.25)
CVD – cardiovascular disease; RA – Rheumatoid arthritis; OR – odds ratio; CI – confidence interval.
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screening in secondary care, but this is not noted in
their primary care record. However, if screening led to
additional medications for diabetes, hyperlipidaemia or
hypertension being introduced this would be included
within primary care records. If significant secondary care
screening is occurring but is not recorded, this is likely
to improve with the addition of RA to the QOF compo-
nent of the UK General Practice Contract, which took
effect in April 2013.
In addition, although all patients had at least one diag-
nostic Read code for RA, we were unable to stratify pa-
tients by disease activity, severity or disease modifying
anti-rheumatic drug (DMARD) treatment, as many of
the hospital prescribed DMARDs such as parenteral
methotrexate would not have been captured. Neverthe-
less the screening recommendations do not stratify RA
in this way, and we do not expect that the recording of
RA in primary care, or CVD screening as a result of an
RA diagnosis, to be biased by the severity of disease.
Hence, the lack of disease activity information is un-
likely to account for the results. It is also possible that
some patients with a single RA code did not actually
have RA. This could have been avoided by the use of
an algorithm for the diagnosis of RA (e.g. [20]). How-
ever, what is important in the primary care context is
that patients that the GP considers to have RA areTable 4 The effect of comorbidity on standard CVD screening
Number of patients (n (%)) Unadjus
No RA or DM 1071 (67.0) 1.00
RA only 353 (22.1) 0.96 (0.74
DM only 127 (7.9) 12.15 (7.5
RA +DM 48 (3.0) 14.91 (6.6
No RA or HTN 651 (40.7) 1.00
RA only 192 (12.0) 1.11 (0.74
HTN only 547 (34.2) 5.34 (4.11
RA +HTN 209 (13.1) 4.36 (3.11
No RA or HLP 800 (50.0) 1.00
RA only 267 (16.7) 1.09 (0.76
HLP only 398 (24.9) 12.31 (9.2
RA +HLP 134 (8.4) 11.50 (7.6
RA – Rheumatoid arthritis; HTN – hypertension; HLP – hyperlipidaemia; OR – odds rscreened for CVD risk factors, and the use of a single
RA code allows this to be tested.
This study is in keeping with existing work that has
suggested that CVD screening is sub-optimal in RA pa-
tients [17-19,21-24] and perhaps also suggests that the
omission of RA from CVD risk scores such as Framing-
ham and the Joint British Societies may be masking the
issue of CVD risk in patients with RA. Previous work
also suggests that effective identification of, and incen-
tives to screen, high risk groups can lead to changes in
practice, e.g. [25].
There are several possible hypotheses as to why RA
does not lead to additional CVD screening. First, it may
be that the increased risk of CVD in RA is not
recognised in primary care. In a study by Bell and Rowe
[23], only 32% of family physicians identified RA as an
independent risk factor for CVD, and only 15% assessed
their patients for primary CVD prevention. Second, it
may be that the excess CVD risk is recognised, but there
is confusion over whose responsibility it is to screen
for CVD, especially in complex RA patients, who may
already be taking a number of medications or under
regular secondary care follow up.
In common with the existing literature, the presence
of comorbidity, especially diabetes was associated with
screening [24,26], suggesting that despite the CVD risks
being similar in RA and diabetes [10,11], screeningted (OR (95% CI)) Age and gender adjusted (OR (95% CI))
1.00
, 1.26) 0.96 (0.72, 1.24)
3, 19.61) 11.14 (6.86, 18.11)
2, 33.61) 15.32 (6.70, 35.02)
1.00
, 1.68) 1.16 (0.77, 1.76)
, 6.94) 4.82 (3.67, 6.35)
, 6.11) 3.82 (2.70, 5.42)
1.00
, 1.58) 1.07 (0.68, 1.66)
5, 16.38) 9.78 (6.98, 12.87)
2, 17.35) 8.15 (5.40, 12.31)
atio; CI – confidence interval.
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likely to receive CVD screening. This may in part be
explained by the higher population prevalence of diabetes
(5.1% UK adults [27]) compared to RA (1% [28]), meaning
the average family physician will manage significantly
more patients with diabetes compared to those with RA.
In addition, many of those with diabetes mellitus may be
managed exclusively in primary care, and in the UK family
physicians are incentivised to screen patients with diabetes
for CVD under the Quality and Outcomes Framework
(QOF) component of the General Practice Contract. This
has been shown to lead to improved quality of diabetes
care [12,13]. Similar quality indicators relating to CVD
risk assessment have recently been introduced [29], in that
RA patients aged between 30–85 will be expected to have
had an annual CVD risk assessment, using a CVD risk
assessment tool adjusted for RA. Given the effect of
incentivising care on screening rates in diabetes it may be
that these indicators will improve CVD screening rates for
patients with RA, as might the recent introduction of
NHS Health Checks for patients over the age of 40, espe-
cially if patients with RA are actively targeted.Conclusions
In summary, this study has shown that despite the wealth
of literature and national guidelines, current practice for
CVD screening of RA patients in primary care is subopti-
mal. This study suggests that more needs to be done to in-
crease awareness in primary care physicians, nurses and
patients regarding the excess CVD risk associated with
RA and to agree how this excess risk should be managed.
The inclusion of new incentives within the GP contract
for cardiovascular screening in RA may lead to improved
management for these patients.Competing interests
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